Two signals, one molecule
Laboratory stage · Published November 2022
Can one molecule activate two different receptors?
Subject One stands between two brass bells. He rings one and waits for the other to answer. Doctide gives him a pencil instead. “Before the performance, we check the instrument.” The visitor starts a diagram; neither bell counts as evidence.
What changes here
Survodutide was designed to activate glucagon and GLP-1 receptors; laboratory activity alone cannot establish treatment benefit. [1]
Read the study details & dates
Receptor assays before clinical conclusions
Zimmermann and colleagues tested BI 456906, later named survodutide, in receptor assays and isolated tissues. Comparators included native hormones and GLP-1 agonists. The modified peptide activated both receptor systems. Human isolated islets are laboratory material, not trial participants. A clinical phase or NCT identifier does not apply. [1]
What this does not establish
A mechanism does not establish long-term safety or clinical superiority. This chapter describes selected discovery experiments, not the complete regulatory toxicology dossier.
Original sources
Primary discovery paper reviewed through Europe PMC full-text XML, October 27, 2026.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story